Allogene Therapeutics Inc

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allogene Therapeutics reports strong Q4 performance and financial stability

Allogene Therapeutics showcased promising clinical data for its AlloCAR T therapy and emphasized a strong financial position. While facing challenges in manufacturing optimization, the company is focused on pivotal trials and cost management. Opportunities for growth include product reintroductions and ongoing program updates.

Allogene reports positive Q1 results, eyes partnerships for growth

Allogene Therapeutics showcased positive patient responses and financial prudence in Q1 2023, underlining its commitment to innovation and efficiency.
While facing resource limitations and challenges in product development, the company is exploring partnerships and expansion opportunities for future growth.
Overall, Allogene's strategic focus on patient care, operational excellence, and therapeutic advancements positions it well for continued success in the biopharmaceutical industry.

Allogene Therapeutics reports Q2 losses but showcases promising CAR-T results

Allogene Therapeutics' Q2 2023 performance reflects strategic investments in R&D and operational expenses, supported by a strong balance sheet and promising results in their allogeneic CAR-T program.
While facing challenges in patient access, manufacturing, and collaborations, the company is well-positioned to capitalize on opportunities in global expansion, next-gen technologies, and clinical trial progress.
With a focus on innovation, operational efficiency, and market expansion, Allogene Therapeutics navigates complexities in the CAR-T space to drive growth and advance its therapeutic offerings.

Allogene Therapeutics excels in Q3, poised for CAR T leadership

Allogene Therapeutics showcased strong financials, promising clinical trial results, and strategic leadership changes.
The focus on allogeneic CAR T therapy positions the company for growth and market leadership.
Challenges include competition, regulatory complexities, and ensuring manufacturing scalability.
Opportunities lie in expanding trials, presenting at key conferences, and advancing pipeline innovations.

Allogene Therapeutics reports robust financials and advances innovative therapies

Allogene Therapeutics showcased strong financials, innovative trials, and strategic partnerships, positioning the company for future growth and therapeutic advancements.
While facing challenges from external factors and clinical complexities, Allogene has opportunities to expand its therapeutic reach and enhance treatment efficacy.
Investor interest in Allogene's pipeline and the company's positive response to inquiries reflect a promising outlook for continued development and success.
Allogene's focus on cutting-edge therapies, financial stability, and community engagement underscore its commitment to advancing patient care and addressing unmet medical needs.

Allogene Therapeutics reports strong Q1 performance and eyes autoimmune expansion

Allogene Therapeutics demonstrated solid financial performance in Q1 2024, with strategic investments and a focus on core programs.
Challenges in enrollment processes, dosing strategies, and safety considerations underscore the complexities of therapeutic development.
Opportunities lie in expanding into autoimmune indications, leveraging unique treatment approaches, and impacting the CAR T treatment landscape.

Allogene Therapeutics reports Q2 momentum, faces challenges, eyes growth

Allogene Therapeutics demonstrated positive momentum and strategic planning in Q2 2024, focusing on key programs and collaborations.
While financial challenges exist, the company's strengths in manufacturing capabilities and program advancements provide a solid foundation.
Addressing challenges like differentiation in the autoimmune space and financial losses will be crucial for sustained growth.
Opportunities for growth are present in continued program progress, FDA collaborations, and strategic milestones like IND filings.

Allogene Therapeutics advances in CAR-T therapies amidst financial challenges

Allogene Therapeutics showcased promising advancements in Q3 2024 across multiple therapeutic areas, positioning itself as a key player in the CAR-T therapy space.
While financial challenges persist, the company's strong cash position and strategic focus on transformative therapies provide a solid foundation for future growth.
Addressing concerns raised by analysts regarding data, safety, and trial participation will be crucial for maintaining investor confidence and advancing clinical development.
Overall, Allogene's dedication to pioneering treatments in oncology and autoimmune diseases underscores its potential for long-term success and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company's next generation DaggerTM platform technology at the Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Banff, Alberta, Canada.

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

New York, New York--(Newsfile Corp. - January 25, 2023) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Allogene Therapeutics, Inc. (NASDAQ: ALLO) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own ALLO please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245.

Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC). The findings were published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock?

ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

Bed Bath & Beyond

Beyond Meat

Carvana

Heron Therapeutics

Marathon Digital Holdings

Silvergate Capital Corp

The Beauty Health Company

Upstart Holdings

Wayfair

Shorting stocks is still a viable strategy for experienced investors who are active in the stock market. Here is a look back at the most shorted stocks of December 2022.

Looking Back At The 10 Most Shorted Stocks Of December 2022

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:45 p.m. Pacific Time. The event will be held in San Francisco at the Westin St. Francis.

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates

Allogene Appoints Zachary J. Roberts, M.D.

Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround

The stock price of Allogene Therapeutics (ALLO) fell by 8.11% in the most recent trading session. This is why.

Why The Allogene Therapeutics (ALLO) Stock Fell 8.11%

The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 158.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 159%: Read This Before Placing a Bet

Allogene Therapeutics, Inc. has an excellent pedigree and superior science. However, with it being a leader in a difficult field, investing in Allogene Therapeutics, Inc. here is tough.

Allogene: Pioneering Allogeneic CAR-T Developer With No Near-Term Catalysts

AST SpaceMobile

Mullen Automotive

PMV Pharmaceuticals

Tricida Inc

Vertex Energy

The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among investors have been especially unsettling for companies with weak financial positions.

Top 10 most-shorted stocks as of November 2022

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today hosted an R&D Showcase providing an extensive overview of pipeline advances from three clinical stage AlloCAR T programs. The event also included panel discussions with leading experts on the potential for these programs to substantially improve patient care and access if approved. Clinical updates on the Company's hematologic franchises focused on investigational products targeting CD19 and BCMA for the treatment of large B cell lymphoma (LBCL) and multiple myeloma (MM), respectively. The solid tumor presentation provided the first look at initial clinical data on ALLO-316, an AlloCAR T product candidate targeting CD70 for the treatment of clear cell renal cell carcinoma (RCC).

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

The consensus price target hints at a 137.5% upside potential for Allogene Therapeutics (ALLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 137%: Here's is How to Trade

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer will host a Research & Development Showcase to provide a comprehensive overview of its CD19 and BCMA programs on November 29, 2022. The Company will also participate in five upcoming investor conferences.

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.

Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will present updated data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma, in a poster presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022 in New Orleans, LA.

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Christine Cassiano - CCO David Chang - President and CEO Rafael Amado - EVP, Research & Development and CMO Eric Schmidt - CFO Conference Call Participants Andrea Tan - Goldman Sachs Michael Yee - Jefferies Tyler Van Buren - Cowen Asthika Goonewardene - Truist Raju Prasad - William Blair Reni Benjamin - JMP Securities Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Michael Schmidt - Guggenheim Partners Luca Issi - RBC Capital Markets Jason Gerberry - Bank of America Kalpit Patel - B. Riley David Dai - SMBC Jack Allen - Baird Brian Cheng - JPMorgan Robert Burns - H.C.

Allogene Therapeutics, Inc. (ALLO) Q3 2022 Earnings Call Transcript

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended September 30, 2022.

Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced it has completed the buildout of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China.

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today launched CAR T Together™, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers.

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

News for Allogene Therapeutics Inc Stock (ALLO)